People: IGI Laboratories Inc (IG)

IG on American Stock Exchange

9.24USD
26 Dec 2014
Price Change (% chg)

$0.13 (+1.43%)
Prev Close
$9.11
Open
$9.12
Day's High
$9.24
Day's Low
$8.77
Volume
472,338
Avg. Vol
896,085
52-wk High
$11.28
52-wk Low
$2.86

Search Stocks

Summary

Name Age Since Current Position

Jason Grenfell-Gardner

39 2012 President, Chief Executive Officer, Director

Jenniffer Collins

45 2011 Chief Financial Officer

Steven Koehler

60 2014 Director

Narendra Borkar

73 2009 Independent Director

Bhaskar Chaudhuri

59 2010 Independent Director

James Gale

64 2009 Independent Director

Biographies

Name Description

Jason Grenfell-Gardner

Mr. Jason Grenfell-Gardner is President, Chief Executive Officer, Director of IGI Laboratories, Inc. Since July 2008, Prior to joining IGI, Mr. Grenfell-Gardner spent over eight years at Hikma Pharmaceuticals, PLC, and its subsidiaries including West-Ward Pharmaceuticals in the United States. He served in a number of roles, most recently as Senior Vice President of Sales and Marketing from 2008-2012. Before joining Hikma, Mr. Grenfell-Gardner worked throughout Central and Eastern Europe as a partner at Trigon Capital, a boutique investment bank, focused on mergers and acquisitions. During his time in that region, Mr. Grenfell-Gardner served as Chairman of the board of directors of Sanitas Pharmaceuticals, as well as other board positions. Mr. Grenfell-Gardner holds an MA (Hons) in Economics from the University of St Andrews in Scotland (1998) and an MBA from INSEAD (2004).

Jenniffer Collins

Ms. Jenniffer Collins is Chief Financial Officer of IGI Laboratories Inc., since July 21, 2011. Ms. Collins has over twenty years of experience in accounting and finance. Prior to joining IGI, she most recently served, from October 2006 to July 2011, as Vice President-Treasurer and previously the Corporate Controller at the Lightstone Group, a privately held real estate firm, and The Lightstone Value Plus REIT, a publicly traded real estate investment trust. From January 2004 through October 2006, Ms. Collins also served as Corporate Controller for Orchid Cellmark, Inc., a publicly held biotechnology company, and from July 2001 through January 2004, Ms. Collins served as Director of Finance and Investor Relations for Tellium, Inc., a publicly held optical switching company, which was purchased by Zhone Technologies, Inc. in November 2003. Her background also includes seven years of public accounting experience, including at Pricewaterhouse Coopers. Ms. Collins earned her CPA in New Jersey in 1993 and graduated with a B.S. in accounting from Lehigh University.

Steven Koehler

Steven Hubrig Koehler has been appointed as Director of IGI Laboratories, Inc. Mr. Koehler retired from Merck & Co in September of 2011, where he served as Vice President, Schering-Plough Controller and Special Projects. Prior to this role, Mr. Koehler served as the Vice President, Corporate Controller of Schering-Plough Corporation, where he also served as Chief Accounting Officer and was directly responsible for accounting and internal control matters worldwide. Before joining Schering-Plough Corporation, he served in several capacities at The Medicines Company, including SVP and Chief Financial Officer. Prior to The Medicines Company, Mr. Koehler served in various executive and senior level positions at Vion Pharmaceuticals, Inc., Knoll Pharmaceuticals, Inc., a wholly owned subsidiary of BASF Corporation, Boots Pharmaceuticals, Inc. and American Hospital Supply Corporation, and then with Baxter International after a merger in 1985. Mr. Koehler began his career at Arthur Andersen in Chicago, holds a B.A. from Duke University, and an MBA degree from the Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant.

Narendra Borkar

Mr. Narendra N. Borkar is Independent Director of IGI Laboratories, Inc., since September 2009. Mr. Borkar has served as Executive Officer of Aurobindo Pharma USA (2004-2006), Chief Executive Officer of Caraco Pharmaceutical Laboratories (1997-2003), various senior roles for Novartis (formerly Ciba-Geigy) (1981-1997), General Manager of Apte Amalgamation (1979-1981), Engineer for Hoffman La Roche (1976-1979), Project Manager for Union Carbide Corp. and Project Manager for Merck & Company, Inc. (1966-1976).

Bhaskar Chaudhuri

Dr. Bhaskar Chaudhuri, Ph.D., is Independent Director of IGI Laboratories, Inc., since December 2010. Mr. Chaudhuri has more than 20 years’ experience in pharmaceutical management, research and development. Since June 2011, he has been the Operating Partner at Frazier Healthcare. Mr. Chaudhuri served as President of Valeant Pharmaceuticals International until September 2010. Prior to joining Valeant in January 2009, Mr. Chaudhuri served for seven years as Dow’s President and Chief Executive Officer and a member of Dow’s board of directors from 2003 to 2008, at which time Dow was acquired by Valeant. Prior to that, Mr. Chaudhuri served as Executive Vice President of Scientific Affairs at Bertek Pharmaceuticals, a subsidiary of Mylan Laboratories. Prior to his positions at Bertek, Mr. Chaudhuri served as the General Manager of the Dermatology Division of Mylan Laboratories. Mr. Chaudhuri joined Mylan through the acquisition of Penederm, Inc., where he worked from 1992 to 1998 in a number of senior positions before becoming the Vice President of R&D. Mr. Chaudhuri holds a Doctorate in Physical Pharmacy from the University of Louisiana, a Masters of Science in Industrial Pharmacy and a Bachelors of Science in Pharmacy from India.

James Gale

Mr. James C. Gale is Independent Director of IGI Laboratories Inc., since May 2009. He is Founding Partner of Signet Healthcare Partners. Prior to founding Signet, Mr. Gale was head of principal investment activities and investment banking at Gruntal & Co., LLC. Prior to joining Gruntal, Mr. Gale originated and managed private equity investments for Home Insurance Co., Gruntal’s parent. Earlier in his career, Mr. Gale was a senior Investment Banker at E.F. Hutton & Co. Mr. Gale is currently the Chairman of the Board of Alpex Pharma SA and Pfenex, Inc. and also serves on the board of directors of Arbor Pharmaceuticals, Spepharm AG and Knight Therapeutics. Mr. Gale holds a Masters of Business Administration from the University of Chicago.

Basic Compensation

Name Fiscal Year Total

Jason Grenfell-Gardner

1,522,290

Jenniffer Collins

287,433

Steven Koehler

--

Narendra Borkar

--

Bhaskar Chaudhuri

--

James Gale

--
As Of 30 Dec 2013

Options Compensation

Search Stocks